289 related articles for article (PubMed ID: 37987270)
21. The Efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for Post-traumatic Stress Disorder in Humans: A Systematic Review and Meta-Analysis.
Tedesco S; Gajaram G; Chida S; Ahmad A; Pentak M; Kelada M; Lewis L; Krishnan D; Tran C; Soetan OT; Mukona LT; Jolayemi A
Cureus; 2021 May; 13(5):e15070. PubMed ID: 34150406
[No Abstract] [Full Text] [Related]
22. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.
Marseille E; Kahn JG; Yazar-Klosinski B; Doblin R
PLoS One; 2020; 15(10):e0239997. PubMed ID: 33052965
[TBL] [Abstract][Full Text] [Related]
23. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Ot'alora G M; Grigsby J; Poulter B; Van Derveer JW; Giron SG; Jerome L; Feduccia AA; Hamilton S; Yazar-Klosinski B; Emerson A; Mithoefer MC; Doblin R
J Psychopharmacol; 2018 Dec; 32(12):1295-1307. PubMed ID: 30371148
[TBL] [Abstract][Full Text] [Related]
24. Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.
Ponte L; Jerome L; Hamilton S; Mithoefer MC; Yazar-Klosinski BB; Vermetten E; Feduccia AA
J Trauma Stress; 2021 Aug; 34(4):851-863. PubMed ID: 34114250
[TBL] [Abstract][Full Text] [Related]
25. MDMA to Treat PTSD in Adults.
Latimer D; Stocker MD; Sayers K; Green J; Kaye AM; Abd-Elsayed A; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Jun; 51(3):125-149. PubMed ID: 34421149
[TBL] [Abstract][Full Text] [Related]
26. Progress and promise for the MDMA drug development program.
Feduccia AA; Holland J; Mithoefer MC
Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674
[TBL] [Abstract][Full Text] [Related]
27. Review of potential psychedelic treatments for PTSD.
Henner RL; Keshavan MS; Hill KP
J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
[TBL] [Abstract][Full Text] [Related]
28. Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.
Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR
Pharmacol Ther; 2022 Nov; 239():108195. PubMed ID: 35489438
[TBL] [Abstract][Full Text] [Related]
29. Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Thal SB; Lommen MJJ
J Contemp Psychother; 2018; 48(2):99-108. PubMed ID: 29720767
[TBL] [Abstract][Full Text] [Related]
30. Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe PTSD: an interpretative phenomenological analysis of clinical integration sessions.
Godes M; Lucas J; Vermetten E
Front Psychiatry; 2023; 14():957824. PubMed ID: 37484678
[TBL] [Abstract][Full Text] [Related]
31. MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn't.
Morgan L
Ann Gen Psychiatry; 2020; 19():33. PubMed ID: 32435270
[TBL] [Abstract][Full Text] [Related]
32. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis.
Smith KW; Sicignano DJ; Hernandez AV; White CM
J Clin Pharmacol; 2022 Apr; 62(4):463-471. PubMed ID: 34708874
[TBL] [Abstract][Full Text] [Related]
33. Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy.
Gully BJ; Eaton E; Capone C; Haass-Koffler CL
J Psychopharmacol; 2023 Dec; 37(12):1182-1189. PubMed ID: 38009477
[TBL] [Abstract][Full Text] [Related]
34. Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions.
Schenk S; Newcombe D
J Clin Psychopharmacol; 2018 Dec; 38(6):632-638. PubMed ID: 30303861
[TBL] [Abstract][Full Text] [Related]
35. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD.
Brewerton TD; Lafrance A; Mithoefer MC
Med Hypotheses; 2021 Jan; 146():110367. PubMed ID: 33203569
[TBL] [Abstract][Full Text] [Related]
36. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy.
Sessa B; Higbed L; Nutt D
Front Psychiatry; 2019; 10():138. PubMed ID: 30949077
[TBL] [Abstract][Full Text] [Related]
37. MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial.
Ching TH; Williams MT; Wang JB; Jerome L; Yazar-Klosinski B; Emerson A; Doblin R
J Psychopharmacol; 2022 Aug; 36(8):974-986. PubMed ID: 35727042
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Mithoefer MC; Wagner MT; Mithoefer AT; Jerome L; Doblin R
J Psychopharmacol; 2011 Apr; 25(4):439-52. PubMed ID: 20643699
[TBL] [Abstract][Full Text] [Related]
39. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.
Amoroso T
J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955
[TBL] [Abstract][Full Text] [Related]
40. Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.
Roberts NP; Roberts PA; Jones N; Bisson JI
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010204. PubMed ID: 27040448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
